<DOC>
	<DOCNO>NCT00596908</DOCNO>
	<brief_summary>This study design obtain imaging training set use evaluate image future trial . Currently , radiopharmaceutical diagnostic imaging agent approve FDA U.S. use diagnose Parkinson disease relate Parkinsonian syndrome . The diagnosis Parkinsonian syndromes U.S. base clinical criterion . The goal demonstrate 123I-ALTROPANE® paired SPECT image permit accurate early diagnosis Parkinson disease clinical diagnosis general neurologist .</brief_summary>
	<brief_title>123I-ALTROPANE® Reference Image Acquisition Subjects With Diagnostically Uncertain Tremor</brief_title>
	<detailed_description>This prospective , multi-center , non-randomized , open-label , patient clinical trial include 90 subject , male female , 40 year age old . This study design obtain imaging training set use evaluate image future trial . Up ninety subject upper extremity tremor le 2 year duration enrol . Of , least thirty Parkinsonian syndrome subject least thirty non-Parkinsonian syndrome subject diagnose MDS enrol . Subjects participate three study visit course study period . The screening visit include assessment eligibility well collection MDS diagnosis . The second visit , subject receive single intravenous injection 123I-ALTROPANE® follow SPECT imaging , include appropriate safety assessment dose . The third visit include follow-up safety . The subject ' participation study range 30 40 day .</detailed_description>
	<mesh_term>Tremor</mesh_term>
	<criteria>1 . Subjects must provide write informed consent prior initiation study related procedure ; 2 . Subjects ≥ 40 year age ; 3 . Subjects upper extremity tremor &lt; 2 year duration . 1 . Any clinically significant acute unstable physical psychological illness base medical history physical examination Visit 1 , determine Principal Investigator ; 2 . Any unexpected clinically significant abnormal laboratory ECG result obtain Visit 1 determine Principal Investigator ; 3 . Any history drug , narcotic , alcohol abuse within 2 year prior date informed consent , define Diagnostic Statistical Manual American Psychiatric Association , 4th Edition ( DSMIVR { American Psychiatric Association , 1994 # 2 } ) ; 4 . Positive urine drug screen Visit 1 ; 5 . Participation investigational drug device clinical trial within 30 day prior date informed consent ; 6 . Previous participation 123IALTROPANE® trial ; 7 . Any exposure radiopharmaceutical within 30 day prior date informed consent ; 8 . Positive ( + ) pregnancy test Visit 1 and/or Visit 2 ; 9 . Breastfeeding ; 10 . Inability lie supine 1 hour ; 11 . Any significant active thyroid disease ; 12 . Known sensitivity allergy Iodine Iodine containing product ; 13 . A history repeat head injury sustain severe head injury year prior onset tremor ; 14 . A definitive diagnosis encephalitis ; 15 . Any uncontrolled hypertension diabetes ; 16 . Any history cerebrovascular disease ; 17 . Previous evaluation Movement Disorder Specialist ( MDS ) ; 18 . Treatment within previous six ( 6 ) month prior inform consent bupropion , metoclopramide , cinnarizine , flunarizine , methylphenidate , reserpine , modafinil , alpha methyldopa , amphetamine , antipsychotic medication ; 19 . Any treatment antiParkinson 's drug antitremor medication within three ( 3 ) month prior date subject signing informed consent ; 20 . Any new prescription change dose medication chronic condition within four ( 4 ) week Visit 2 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Essential Tremor</keyword>
	<keyword>Parkinsonian Tremor</keyword>
	<keyword>Parkinson Disease</keyword>
	<keyword>Upper Extremity Tremor duration le 2 year</keyword>
</DOC>